نتایج جستجو برای: taxane

تعداد نتایج: 2009  

Journal: :Medical oncology 2013
Xianglin L Du Rohan C Parikh David R Lairson Sharon H Giordano Putao Cen

The aim was to compare the two most commonly recommended chemotherapy regimens (platinum-based chemotherapy and platinum-taxane combination) with non-platinum-based chemotherapy and those with no chemotherapy in a large nationwide and population-based cohort of patients with ovarian cancer with up to 17 years of follow-up. We studied 12,181 patients diagnosed with stages I-IV ovarian cancer at ...

Journal: :Urologic oncology 2016
Jean-Pierre Droz Eleni Efstathiou Asif Yildirim Paula Cabrera Choung Soo Kim Ali Horchani Axel Heidenreich José Augusto Rinck-Junior Simon Hitier Haluk Ӧzen

AIMS To compare the efficacy and tolerability of taxane and nontaxane therapy in senior adults with chemonaïve metastatic castration-resistant prostate cancer (mCRPC), and examine the effect of patient health status on outcomes. PATIENTS AND METHODS Between 2009 and 2011, 333 patients aged≥70 years with mCRPC were enrolled in a prospective international registry. Patients were categorized as ...

Journal: :iranian journal of cancer prevention 0
leila pourali women's health research center, mashhad university of medical sciences, mashhad, iran. ali taghizadeh kermani surgical oncology research center, mashhad university of medical sciences, mashhad, iran. mohammad reza ghavamnasiri cancer research center, mashhad university of medical sciences, mashhad, iran. fahimeh khoshroo cancer research center, mashhad university of medical sciences, mashhad, iran. sare hosseini cancer research center, mashhad university of medical sciences, mashhad, iran. mehdi asadi surgical oncology research center, mashhad university of medical sciences, mashhad, iran.

background: chemotherapy-induced amenorrhea is one of long term side effects of adjuvant chemotherapy in patients with breast cancer which may interfere with their future reproductive function. although amenorrhea is well recognized, the actual incidence following taxanes remains uncertain. methods: in a cross sectional study, we identified breast cancer patients aged 45 years or younger who we...

Journal: :Canadian journal of health technologies 2022


 CADTH recommends that Enhertu be reimbursed by public drug plans for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer if certain conditions are met.
 should only covered to treat is (i.e., has spread beyond initial tumour site) who have previously received trastuzumab and taxane locally advanced disease, tumours progressed within 6 months n...

2011
Nguyen Tan Mehnaz Malek Jiping Zha Peng Yue Robert Kassees Leanne Berry Wayne J. Fairbrother Deepak Sampath Lisa D. Belmont

Purpose: To explore the potential of navitoclax in combination with taxane-based chemotherapy in the treatment of non–small cell lung cancer (NSCLC) by defining mechanism of synergy and identifying correlative biomarkers. Experimental Design:We treated a panel of NSCLC lines with a dosematrix of paclitaxel and navitoclax (formerly ABT-263), an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (1), and eval...

2010
Z. Nahleh J. Pruemer J. Lafollette S. Sweany

PURPOSE Melatonin has neuroprotective effects in animal studies and has been suggested to decrease adverse reactions of chemotherapy including neuropathy. This pilot trial aimed at assessing whether melatonin, given during taxane chemotherapy for breast cancer, will decrease the incidence and/or severity of neuropathy. METHODS Twenty two consecutive patients beginning chemotherapy for breast ...

2013
Soyoung Im Changyoung Yoo Ji-Han Jung Ye-Won Jeon Young Jin Suh Youn Soo Lee Hyun Joo Choi

BACKGROUND The microtubule-associated protein Tau binds to both inner and outer surfaces of microtubules, leading to tubulin assembly and microtubule stabilization. The aim of this study was to evaluate the significance of Tau, α-tubulin, and βIII-tubulin expression in breast carcinoma and to assess their relationships with disease progression in the context of taxane treatment. METHODS Immun...

Journal: :Cancer research 2001
D C Yu Y Chen J Dilley Y Li M Embry H Zhang N Nguyen P Amin J Oh D R Henderson

CV787, a PSA+ prostate cell-specific adenovirus variant, is currently in Phase I/II clinical trials for the treatment of prostate cancer. We have previously demonstrated that a single administration of CV787 at 1 x 10(11) particle/animal could eliminate established tumors within 6 weeks in nude mouse xenografts (Yu et al., Cancer Res., 59: 4200-4203, 1999). We now demonstrate that CV787-mediate...

2014
Yan-Long Yang Xiu-Ping Luo Lei Xian

BACKGROUND A number of studies have examined the relationship between the expression of the class III β-tubulin (TUBB3) and the treatment responses to the taxane/vinorebine-based chemotherapy in patients with non-small cell lung cancer (NSCLC). However, the results of these studies were inconsistent and inconclusive. Therefore, we conducted an up-to-date meta-analysis to evaluate the prognostic...

2015
Stefano Kim Frederic Fiteni Sophie Paget-Bailly François Ghiringhelli Zaher Lakkis Marine Jary Francine Fein Franck Bonnetain Christophe Mariette Christophe Borg

The benefit of preoperative chemotherapy in resectable gastroesophageal adenocarcinomas was not observed in signet ring cell subtype. However, the potential interest of taxane-based preoperative chemotherapy on this subtype is still an unresolved issue. Nineteen patients with localized signet ring cell adenocarcinomas received taxane-based regimens, and 17 patients underwent surgery. Complete r...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید